M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Azacitidine Maintenance Therapy After Allogeneic Bone Marrow Transplantation (Allo BMT)

Phase 1

Completed

Conditions: Myelodysplastic Syndrome
Leukemia

Interventions: Drug: Azacitidine

First Posted Date: 2006-07-11

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 90

Registration Number: NCT00350818

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

Phase 1

Completed

Conditions: Acute Lymphocytic Leukemia

Interventions: Drug: Decitabine

First Posted Date: 2006-07-07

Last Posted Date: 2014-10-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00349596

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: Celecoxib
Drug: Cisplatin
Drug: CPT-11
Radiation: Concurrent Thoracic Radiation Therapy

First Posted Date: 2006-06-30

Last Posted Date: 2012-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00346801

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Elizabeth Registry for Low Grade Ovarian Cancer

Completed

Conditions: Ovarian Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2006-06-28

Last Posted Date: 2015-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT00345709

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma

Phase 2

Completed

Conditions: Cancer of the Gallbladder
Cancer of the Biliary Tract

Interventions: Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2006-06-20

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT00338988

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Cetuximab
Drug: Gemcitabine
Drug: Oxaliplatin
Drug: Capecitabine
Radiation: Radiotherapy

First Posted Date: 2006-06-20

Last Posted Date: 2013-03-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 69

Registration Number: NCT00338039

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Biological: Dendritic Cell Immunization
Biological: Intrathecal T-Cells
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Intrathecal Interleukin-2
Biological: T-Cells
Biological: Interleukin-2
Drug: Mesna

First Posted Date: 2006-06-20

Last Posted Date: 2025-04-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1230

Registration Number: NCT00338377

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer

Phase 2

Completed

Conditions: Estrogen Receptor Positive
Anatomic Stage IV Breast Cancer AJCC v8
PDGFR Positive
KIT Positive
Postmenopausal
Progesterone Receptor Positive
Prognostic Stage IV Breast Cancer AJCC v8

Interventions: Drug: Imatinib Mesylate
Drug: Letrozole

First Posted Date: 2006-06-20

Last Posted Date: 2020-01-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 59

Registration Number: NCT00338728

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Preop Chemoradiation Resectable Pancreas

Phase 2

Completed

Conditions: Pancreatic Neoplasms

Interventions: Drug: Avastin (Bevacizumab)
Drug: Gemcitabine
Procedure: Radiation Therapy

First Posted Date: 2006-06-14

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00336648

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Paclitaxel
Drug: Epirubicin

First Posted Date: 2006-06-14

Last Posted Date: 2012-02-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 273

Registration Number: NCT00336791

Locations: 🇪🇸
Grupo Español de Investigacion en Cancer de Mama, Madrid, Spain
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇲🇽
Centro Medico Nacional de Occidente, Guadalajara, Mexico

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy